Photodynamic therapy for polypoidal choroidal vasculopathy

Progress in Retinal and Eye Research

Volumn 37, Issue , 2013, Pages 182-199

  Nowak Sliwinska, Patrycja ^a,b   van den Bergh, Hubert ^a   Sickenberg, Michel ^c   Koh, Adrian H C ^d  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Save Sight Foundation   (Switzerland)

^d Eye and Retina Surgeons   (Singapore)

Author keywords

Age related macular degeneration; Anti Angiogenesis; Choroidal neovascularization; Optical coherence tomography; Polypoidal choroidal vasculopathy; Visudyne photodynamic therapy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BEVACIZUMAB; CASPASE 3; CASPASE 9; COMBRETASTATIN A4 PHOSPHATE; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; CYTOCHROME C; DEXAMETHASONE; HIGH TEMPERATURE REQUIRED FACTOR A1; MEMBRANE PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PAZOPANIB; PEGAPTANIB; PLACEBO; PROCASPASE 9; RANIBIZUMAB; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VATALANIB; VERTEPORFIN; VOLOCIXIMAB;

APOPTOSIS; BRUCH MEMBRANE; DOWN REGULATION; DRUG MEGADOSE; EXUDATIVE MACULAR DEGENERATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; HUMAN; HYALINE DEGENERATION; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; MONOTHERAPY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA ANGIOGRAPHY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; REVIEW; SCANNING LASER OPHTHALMOSCOPE; SCAR FORMATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UPREGULATION; VISUAL ACUITY; VITREOUS HEMORRHAGE;

11-CIS-RAL; 11-CIS-REH; 11-CIS-RETINAL; 11-CIS-RETINYL ESTER HYDROLASE; A2E; A2PE; ABCA4; AGE-RELATED EYE DISEASE STUDY; AGE-RELATED MACULAR DEGENERATION; ALL-TRANS-RAL; ALL-TRANS-RE; ALL-TRANS-RETINAL; ALL-TRANS-RETINAL ESTER; AMD; ANTI-ANGIOGENESIS; AREDS; ATP-BINDING CASSETTE TRANSPORTER 4; BCVA; BENZOPORPHYRIN DERIVATIVE MONOACID RING A; BEST-CORRECTED VISUAL ACUITY; BPDMA; BRANCHING VASCULAR NETWORK; BVN; CELLULAR RETINALDEHYDE-BINDING PROTEIN; CFH; CHOROIDAL NEOVASCULARIZATION; CNV; COMPLEMENT FACTOR H; CRALBP; DI-RETINOID-PYRIDINIUM-ETHANOLAMINE; EARLY TREATMENT DIABETIC RETINOPATHY STUDY; ELASTIN GENE; ELN; EPITHELIUM-DERIVED GROWTH FACTOR; ETDRS; FEEDER VESSELS; FV; HIGH TEMPERATURE REQUIRED FACTOR A1; HTRA1; ICGA; INDOCYANINE GREEN ANGIOGRAPHY; INTRAVITREAL RANIBIZUMAB; INTRAVITREAL TRIAMCINOLONE ACETONIDE; IVB; IVTA; LECITHIN:RETINOL ACYLTRANSFERASE; LRAT; MAMMALIAN TARGET OF RAPAMYCIN; METARHODOPSIN II; MII; MTOR; N-RET-PE; N-RETINYLIDINE-PHOSPHATIDYL ETHANOLAMINE; OCT; OPTICAL COHERENCE TOMOGRAPHY; OS; OUTER SEGMENT; PCV; PDGF; PE; PED; PEGF; PERMEABILITY TRANSITION PORE COMPLEX; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLPYRIDINIUM-BISRETINOID; PIGMENT EPITHELIAL DETACHMENT; PLATELET-DERIVED GROWTH FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; PTPC; RDH; REACTIVE OXYGEN SPECIES; RETINAL PIGMENTED EPITHELIUM DETACHMENT; RETINOL DEHYDROGENASE ENZYMES; ROS; RPED; SINGLE NUCLEOTIDE POLYMORPHISM; SMA; SMOOTH MUSCLE ACTIN; SNP; V(®)-PDT; VASCULAR DISRUPTING AGENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VDA; VEGF-A; VISUDYNE(®)-PHOTODYNAMIC THERAPY; VON WILLEBRAND FACTOR; VWF;

ANGIOGENESIS INHIBITORS; CHOROID DISEASES; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LASER THERAPY, LOW-LEVEL; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84887407018     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.09.003     Document Type: Review

References (149)

1. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am. J. Ophthalmol. 2003, 136:1049-1061.
2. Safety Study of High-dose Ranibizumab for Polypoidal Choroidal Vasculopathy (PEARL2) 2010, http://clinicaltrials.gov/ct2/show/NCT01248117.
3. Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients with Polypoidal Choroidal Vasculopathy (PCV) 2012, http://clinicaltrials.gov/ct2/show/NCT01023295.
4. Akaza E., Mori R., Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008, 28:717-722.
5. Almasieh M., Wilson A.M., Morquette B., Cueva Vargas J.L., Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 2012, 31:152-181.
6. Ambati J., Ambati B.K., Yoo S.H., Ianchulev S., Adamis A.P. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 2003, 48:257-293.
7. Antoszyk A.N., Tuomi L., Chung C.Y., Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am. J. Ophthalmol. 2008, 145:862-874.
8. Augustin A. Triple therapy for age-related macular degeneration. Retina 2009, 29:S8-S11.
9. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006, 113:363-372. e365.
10. Bakri S.J., Couch S.M., McCannel C.A., Edwards A.O. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009, 29(5):573-578.
11. Ben-Hur E., Heldman E., Crane S.W., Rosenthal I. Release of clotting factors from photosensitized endothelial cells: a possible trigger for blood vessel occlusion by photodynamic therapy. FEBS Lett. 1988, 236:105-108.
12. Bertossi M., Virgintino D., Coltey P., Errede M., Mancini L., Roncali L. Angiogenesis and endothelium phenotype expression in embryonic adrenal gland and cerebellum grafted onto chorioallantoic membrane. Angiogenesis 1999, 3:305-315.
13. Blinder K.J., Blumenkranz M.S., Bressler N.M., Bressler S.B., Donato G., Lewis H., Lim J.I., Menchini U., Miller J.W., Mones J.M., Potter M.J., Pournaras C., Reaves A., Rosenfeld P., Schachat A.P., Schmidt-Erfurth U., Sickenberg M., Singerman L.J., Slakter J.S., Strong H.A., Virgili G., Williams G.A. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003, 110:667-673.
14. Blumenkranz M.S., Bressler N.M., Bressler S.B., Donati G., Fish G.E., Haynes L.A., Lewis H., Miller J.W., Mones J.M., Potter M.J., Pournaras C., Reaves A., Rosenfeld P.J., Schachat A.P., Schmidt-Erfurth U., Sickenburg M., Singerman L.J., Slakter J.S., Strong A., Vannier S., Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP report no. 5. Arch. Ophthalmol. 2002, 120:1307-1314.
15. Bressler N.M., Arnold J., Benchaboune M., Blumenkranz M.S., Fish G.E., Gragoudas E.S., Lewis H., Schmidt-Erfurth U., Slakter J.S., Bressler S.B., Manos K., Hao Y., Hayes L., Koester J., Reaves A., Strong H.A., Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch. Ophthalmol. 2002, 120:1443-1454.
16. Bressler N.M., Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 2001, 119:198-207.
17. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S., Group A.S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N.Engl. J. Med. 2006, 355:1432-1444.
18. Cackett P., Wong D., Yeo I. Aclassification system for polypoidal choroidal vasculopathy. Retina 2009, 29:187-191.
19. Chang W.H., Petry J.J. Platelets, prostaglandins, and patency in microvascular surgery. J.Microsurg. 1980, 2:27-35.
20. Chen H., Liu K., Chen L.J., Hou P., Chen W., Pang C.P. Genetic associations in polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Mol. Vis. 2012, 18:816-829.
21. Cheng Y., Huang L., Li X., Zhou P., Zeng W., Zhang C. Genetic and functional dissection of ARMS2 in age-related macular degeneration and polypoidal choroidal vasculopathy. PLoS One 2013, 8:e53665.
22. Cho M., Barbazetto I.A., Freund K.B. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2009, 148:70-78. e71.
23. Chung S.E., Kang S.W., Lee J.H., Kim Y.T. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011, 118:840-845.
24. Ciardella A.P., Donsoff I.M., Huang S.J., Costa D.L., Yannuzzi L.A. Polypoidal choroidal vasculopathy. Surv. Ophthalmol. 2004, 49:25-37.
25. Cook K.M., Figg W.D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 2010, 60(4):222-243.
26. Couch S.M., Bakri S.J. Review of combination therapies for neovascular age-related macular degeneration. Semin. Ophthalmol. 2011, 26(3):114-120.
27. Doukas J., Hechtman H.B., Shepro D. Vasoactive amines and eicosanoids interactively regulate both polymorphonuclear leukocyte diapedesis and albumin permeability invitro. Microvasc. Res. 1989, 37:125-137.
28. Ehmann D., Garcia R. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Can. J. Ophthalmol. 2010, 45(1):36-40.
29. Fingar V.H. Vascular effects of photodynamic therapy. J.Clin. Laser Med. Surg. 1996, 14:323-328.
30. Foster T.H., Primavera M.C., Marder V.J., Hilf R., Sporn L.A. Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res. 1991, 51:3261-3266.
31. Gao G., Li Y., Zhang D., Gee S., Crosson C., Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001, 489:270-276.
32. Ghajarnia M., Kurup S., Eller A. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. Semin. Ophthalmol. 2007, 22:127-131.
33. Gilissen M.J., van de Merbel-de Wit L.E., Star W.M., Koster J.F., Sluiter W. Effect of photodynamic therapy on the endothelium-dependent relaxation of isolated rat aortas. Cancer Res. 1993, 53:2548-2552.
34. Giovannini A., Amato G.P., D'Altobrando E., Giuliani M. Optical coherence tomography (OCT) in idiopathic polypoidal choroidal vasculopathy (IPCV). Documenta ophthalmologica. Adv. Ophthalmol. 1999, 97:367-371.
35. Gomez-Ulla F., Gonzalez F., Torreiro M.G. Diode laser photocoagulation in idiopathic polypoidal choroidal vasculopathy. Retina 1998, 18:481-483.
36. Gomi F., Sawa M., Sakaguchi H., Tsujikawa M., Oshima Y., Kamei M., Tano Y. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2008, 92:70-73.
37. Gomi F., Sawa M., Wakabayashi T., Sasamoto Y., Suzuki M., Tsujikawa M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2010, 150:48-54. e41.
38. Goto A., Akahori M., Okamoto H., Minami M., Terauchi N., Haruhata Y., Obazawa M., Noda T., Honda M., Mizota A., Tanaka M., Hayashi T., Tanito M., Ogata N., Iwata T. Genetic analysis of typical wet-type age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese population. J.Ocul. Biol. Dis. Infor. 2009, 2:164-175.
39. Gotoh N., Nakanishi H., Hayashi H., Yamada R., Otani A., Tsujikawa A., Yamashiro K., Tamura H., Saito M., Saito K., Iida T., Matsuda F., Yoshimura N. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2009, 147:1037-1041. 1041 e1031-1032.
40. Green W.R., McDonnell P.J., Yeo J.H. Pathologic features of senile macular degeneration. Ophthalmology 1985, 92(5):615-627.
41. Hamblin M.R., Mroz P. Advances in Photodynamic Therapy 2008, Artech House, Norwood, MA.
42. Hayashi H., Yamashiro K., Gotoh N., Nakanishi H., Nakata I., Tsujikawa A., Otani A., Saito M., Iida T., Matsuo K., Tajima K., Yamada R., Yoshimura N. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. IOVS 2010, 51:5914-5919.
43. Henderson B.W., Owczarczak B., Sweeney J., Gessner T. Effects of photodynamic treatment of platelets or endothelial cells invitro on platelet aggregation. Photochem. Photobiol. 1992, 56:513-521.
44. Hirami Y., Tsujikawa A., Otani A., Yodoi Y., Aikawa H., Mandai M., Yoshimura N. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007, 27:335-341.
45. Honda S., Bessho H., Kondo N., Kusuhara S., Tsukahara Y., Negi A. Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy. Mol. Vis. 2012, 18:2796-2804.
46. Honda S., Imai H., Yamashiro K., Kurimoto Y., Kanamori-Matsui N., Kagotani Y., Tamura Y., Yamamoto H., Ohoto S., Takagi H., Uenishi M., Negi A. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan. Ophthalmol. J. int. d'ophtal. Int. J. ophthalmol. Z. Augenheilkd. 2009, 223:333-338.
47. Hudson H.L. The RADICAL trial: exploring combination therapies. Retina Today 2008, 1:59-62.
48. Iijima H., Iida T., Imai M., Gohdo T., Tsukahara S. Optical coherence tomography of orange-red subretinal lesions in eyes with idiopathic polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2000, 129:21-26.
49. Imamura Y., Engelbert M., Iida T., Freund K.B., Yannuzzi L.A. Polypoidal choroidal vasculopathy: a review. Surv. Ophthalmol. 2010, 55:501-515.
50. Jager R.D., Mieler W.F., Miller J.W. Age-related macular degeneration. N.Engl. J. Med. 2008, 358:2606-2617.
51. Jeon S., Lee W.K., Kim K.S. Adjusted retreatment of polypoidal choroidal vasculopathy after combination therapy: results at 3 Years. Retina 2013, 33:1193-1200.
52. Jirarattanasopa P., Ooto S., Nakata I., Tsujikawa A., Yamashiro K., Oishi A., Yoshimura N. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. IOVS 2012, 53:3663-3672.
53. Kaiser P.K. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefe's Arch. Clin. Exper Ophthalmol. 2006, 244:1132-1142.
54. Kanda A., Chen W., Othman M., Branham K.E., Brooks M., Khanna R., He S., Lyons R., Abecasis G.R., Swaroop A. Avariant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc. Nat. Acad. Sci. USA 2007, 104:16227-16232.
55. Kessel D., Oleinick N.L. Photodynamic therapy and cell death pathways. Meth Mol. Biol. 2010, 635:35-46.
56. Kevany B.M., Palczewski K. Phagocytosis of retinal rod and cone photoreceptors. Physiology 2010, 25:8-15.
57. Klausner J.M., Paterson I.S., Goldman G., Kobzik L., Rodzen C., Lawrence R., Valeri C.R., Shepro D., Hechtman H.B. Postischemic renal injury is mediated by neutrophils and leukotrienes. Am. J. Physiol. 1989, 256:F794-F802.
58. Kleiner R.C., Brucker A.J., Johnston R.L. The posterior uveal bleeding syndrome. Retina 1990, 10:9-17.
59. Koh A., Lee W.K., Chen L.J., Chen S.J., Hashad Y., Kim H., Lai T.Y., Pilz S., Ruamviboonsuk P., Tokaji E., Weisberger A., Lim T.H. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012, 32:1453-1464.
60. Koh A., Lim T.H., Au Eong K.G., Chee C., Ong S.G., Tan N., Yeo I., Wong D. Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy. Singapore Med. J. 2011, 52:232-240.
61. Koh A.H., Chen L.J., Chen S.J., Chen Y., Giridhar A., Iida T., Kim H., Yuk Yau Lai T., Lee W.K., Li X., Han Lim T., Ruamviboonsuk P., Sharma T., Tang S., Yuzawa M. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013, 33:686-716. on behalf of the Expert, P.C.V.P.
62. Koh S., Haimovici R. Photodynamic Therapy of Ocular Diseases 2004, Lippincott Williams & Wilkins, Philadelphia.
63. Kokame G.T., Yeung L., Lai J.C. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br. J. Ophthalmol. 2010, 94:297-301.
64. Kondo N., Honda S., Ishibashi K., Tsukahara Y., Negi A. Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. IOVS 2008, 49:1101-1105.
65. Kwok A.K., Lai T.Y., Chan C.W., Neoh E.L., Lam D.S. Polypoidal choroidal vasculopathy in Chinese patients. Br. J. Ophthalmol. 2002, 86:892-897.
66. Lafaut B.A., Leys A.M., Snyers B., Rasquin F., De Laey J.J. Polypoidal choroidal vasculopathy in Caucasians. Graefe's Arch. Clin. Exper Ophthalmol. 2000, 238:752-759.
67. Lai T.Y., Chan W.M., Liu D.T., Luk F.O., Lam D.S. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2008, 92:661-666.
68. Lai T.Y., Lam C.P., Luk F.O., Chan R.P., Chan W.M., Liu D.T., Lam D.S. Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy. J.Ocul. Pharmacol. Ther. 2010, 26:91-95.
69. Lam D.S., Chan W.M., Liu D.T., Fan D.S., Lai W.W., Chong K.K. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br. J. Ophthalmol. 2004, 88:1315-1319.
70. Laude A., Cackett P.D., Vithana E.N., Yeo I.Y., Wong D., Koh A.H., Wong T.Y., Aung T. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?. Prog. Retin. Eye Res. 2010, 29:19-29.
71. Leal S., Silva R., Figueira J., Cachulo M.L., Pires I., de Abreu J.R., Cunha-Vaz J.G. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up. Retina 2010, 30:1197-1205.
72. Lee K.Y., Vithana E.N., Mathur R., Yong V.H., Yeo I.Y., Thalamuthu A., Lee M.W., Koh A.H., Lim M.C., How A.C., Wong D.W., Aung T. Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy. IOVS 2008, 49:2613-2619.
73. Lee M.W., Yeo I., Wong D., Ang C.L. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye 2009, 23:145-148.
74. Lee S.Y., Kim J.G., Joe S.G., Chung H., Yoon Y.H. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J. Ophthalmol. KJO 2008, 22:92-99.
75. Lim L.S., Mitchell P., Seddon J.M., Holz F.G., Wong T.Y. Age-related macular degeneration. Lancet 2012, 379:1728-1738.
76. Liu X., Zhang K., Huang Y., Kang J.U. Spectroscopic-speckle variance OCT formicrovasculature detection and analysis. Biomed. Opt. Express 2011, 2:2995-3009.
77. Madar-Balakirski N., Tempel-Brami C., Kalchenko V., Brenner O., Varon D., Scherz A., Salomon Y. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One 2010, 5:e10282.
78. Maeda A., Maeda T., Golczak M., Imanishi Y., Leahy P., Kubota R., Palczewski K. Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. Mol. Pharmacol. 2006, 70:1220-1229.
79. Maeda T., Golczak M., Maeda A. Retinal photodamage mediated by all-trans-retinal. Photochem. Photobiol. 2012, 88:1309-1319.
80. Maruko I., Iida T., Saito M., Nagayama D., Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. AM J. Ophthalmol. 2007, 144:15-22.
81. Matsuoka M., Ogata N., Otsuji T., Nishimura T., Takahashi K., Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2004, 88:809-815.
82. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
83. Miller J.W. Treatment of age-related macular degeneration: beyond VEGF. Jpn. J. Ophthalmol. 2010, 54:523-528.
84. Nakashizuka H., Mitsumata M., Okisaka S., Shimada H., Kawamura A., Mori R., Yuzawa M. Clinicopathologic findings in polypoidal choroidal vasculopathy. IOVS 2008, 49:4729-4737.
85. Nakata I., Tsujikawa A., Yamashiro K., Otani A., Ooto S., Akagi-Kurashige Y., Ueda-Arakawa N., Iwama D., Yoshimura N. Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy. Graefe's Arch. Clin. Exper Ophthalmol. 2013, 251:1073-1080.
86. Negrier S., Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest. New Drugs 2012, 30:1791-1801.
87. Nelson J.S., Liaw L.H., Berns M.W. Tumor destruction in photodynamic therapy. Photochem. Photobiol. 1987, 46:829-835.
88. Nowak-Sliwinska P. Anti-angiogenic treatment for exudative age-related macular degeneration: new strategies are underway. Curr. Angiogenesis 2012, 1:318-334.
89. Ogata N., Wada M., Otsuji T., Jo N., Tombran-Tink J., Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. IOVS 2002, 43:1168-1175.
90. Ogletree M.L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed. Proc. 1987, 46:133-138.
91. Ojima Y., Tsujikawa A., Otani A., Hirami Y., Aikawa H., Yoshimura N. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2006, 141:958-960.
92. Okubo A., Sameshima M., Uemura A., Kanda S., Ohba N. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br. J. Ophthalmol. 2002, 86:1093-1098.
93. Ozawa S., Ishikawa K., Ito Y., Nishihara H., Yamakoshi T., Hatta Y., Terasaki H. Differences in macular morphology between polypoidal choroidal vasculopathy and exudative age-related macular degeneration detected by optical coherence tomography. Retina 2009, 29:793-802.
94. Pazos M., Nader H.B. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz. J. Med. Biol. Res. 2007, 40:1025-1035.
95. Radu R.A., Han Y., Bui T.V., Nusinowitz S., Bok D., Lichter J., Widder K., Travis G.H., Mata N.L. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. IIOVS 2005, 46:4393-4401.
96. Reed M.W., Miller F.N., Wieman T.J., Tseng M.T., Pietsch C.G. The effect of photodynamic therapy on the microcirculation. J.Surg. Res. 1988, 45:452-459.
97. Ricci F., Calabrese A., Regine F., Missiroli F., Ciardella A.P. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. Retina 2012, 32:1280-1288.
98. Robertson C.A., Evans D.H., Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J.Photochem. Photobiol. B, Biol. 2009, 96:1-8.
99. Rofagha S., Bhisitkul R.B., Boyer D.S., Sadda S.R., Zhang K., Group S.-U.S. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter Cohort study (SEVEN-UP). Ophthalmology 2013, 10.1016/j.ophtha.2013.03.046.
100. Rosa R.H., Davis J.L., Eifrig C.W. Clinicopathologic reports, case reports, and small case series: clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy. Arch. Ophthalmol. 2002, 120:502-508.
101. Rosenfeld P.J., Boyer D.S., Bressler N.M., Fish G., Grizzard W.S., Hao Y., Hnik P., Hudson H.L., Singerman L., Slakter J.S., Group V.S. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study. Am. J. Ophthalmol. 2007, 144:970-972.
102. Ruamviboonsuk P., Tadarati M., Vanichvaranont S., Hanutsaha P., Pokawattana N. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br. J. Ophthalmol. 2010, 94:1045-1051.
103. Saari J.C. Vitamin A metabolism in rod and cone visual cycles. Ann. Rev. Nutr. 2012, 32:125-145.
104. Sagong M., Lim S., Chang W. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2012, 153:873-882. e872.
105. Saito K., Yamamoto T., Tsuchiya D., Kawasaki R., Haneda S., Yamashita H. Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration. Jpn. J. Ophthalmol. 2009, 53:512-518.
106. Saito M., Iida T., Kano M. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2012, 32:1272-1279.
107. Sato T., Kishi S., Matsumoto H., Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2010, 149:947-954. e941.
108. Sato T., Kishi S., Matsumoto H., Mukai R. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 156:95-105. e101.
109. Schmidt-Erfurth U., Hasan T., Gragoudas E., Michaud N., Flotte T.J., Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994, 101:1953-1961.
110. Schmidt-Erfurth U., Miller J., Sickenberg M., Bunse A., Laqua H., Gragoudas E., Zografos L., Birngruber R., van den Bergh H., Strong A., Manjuris U., Fsadni M., Lane A.M., Piguet B., Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefe's Arch. Clin. Exper Ophthalmol. 1998, 236:365-374.
111. Schmidt-Erfurth U., Wolf S., Group P.S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br. J. Ophthalmol. 2008, 92:1628-1635.
112. Sho K., Takahashi K., Yamada H., Wada M., Nagai Y., Otsuji T., Nishikawa M., Mitsuma Y., Yamazaki Y., Matsumura M., Uyama M. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch. Ophthalmol. 2003, 121:1392-1396.
113. Solomon H.M., Zieve P.D., Krevans J.R. The effect of hematoporphyrin and light on human platelets. II. Uptake of hematoporphyrin. J.Cell Physiol. 1966, 67:281-284.
114. Spaide R.F., Donsoff I., Lam D.L., Yannuzzi L.A., Jampol L.M., Slakter J., Sorenson J., Freund K.B. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. 2002. Retina 2012, 32(Suppl.1):529-535.
115. Spaide R.F., Martin M.L., Slakter J., Yannuzzi L.A., Sorenson J., Guyer D.R., Freund K.B. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am. J. Ophthalmol. 2002, 134:62-68.
116. Spaide R.F., Yannuzzi L.A., Slakter J.S., Sorenson J., Orlach D.A. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995, 15:100-110.
117. Spitzer M.S., Ziemssen F., Bartz-Schmidt K.U., Gelisken F., Szurman P. Treatment of age-related macular degeneration: focus on ranibizumab. Clin. Ophthalmol. 2008, 2:1-14.
118. Spraul C.W., Lang G.E., Grossniklaus H.E., Lang G.K. Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv. Ophthalmol. 1999, 44(Suppl.1):S10-S32.
119. Sridhar S.S., Mackenzie M.J., Hotte S.J., Mukherjee S.D., Tannock I.F., Murray N., Kollmannsberger C., Haider M.A., Chen E.X., Halford R., Wang L., Ivy S.P., Moore M.J. Aphase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs 2013, 31(4):1008-1015.
120. Stangos A.N., Gandhi J.S., Nair-Sahni J., Heimann H., Pournaras C.J., Harding S.P. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am. J. Ophthalmol. 2010, 150:666-673.
121. Stern R.M., Zakov Z.N., Zegarra H., Gutman F.A. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am. J. Ophthalmol. 1985, 100:560-569.
122. Tan C.S., Wong H.T., Lim B.A., Hee O.K., Lim T.H. Polypoidal choroidal vasculopathy causing massive suprachoroidal haemorrhage. Eye 2007, 21:132-133.
123. Tomita K., Tsujikawa A., Yamashiro K., Ooto S., Tamura H., Otani A., Nakayama Y., Yoshimura N. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am. J. Ophthalmol. 2012, 153:68-80. e61.
124. Tong J.P., Chan W.M., Liu D.T., Lai T.Y., Choy K.W., Pang C.P., Lam D.S. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 2006, 141:456-462.
125. Travis G.H., Golczak M., Moise A.R., Palczewski K. Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Ann. Rev. Pharmacol. Tox. 2007, 47:469-512.
126. Tsuchihashi T., Mori K., Ueyama K., Yoneya S. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. Clin. Ophthalmol. 2013, 7:615-620.
127. Tsuchiya D., Yamamoto T., Kawasaki R., Yamashita H. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009, 29(7):960-965.
128. Uyama M., Wada M., Nagai Y., Matsubara T., Matsunaga H., Fukushima I., Takahashi K., Matsumura M. Polypoidal choroidal vasculopathy: natural history. Am. J. Ophthalmol. 2002, 133:639-648.
129. van den Bergh H. Photodynamic therapy of age-related macular degeneration: history and principles. Sem Ophthalmol. 2001, 16:181-200.
130. van den Bergh H., Ballini J.P. Photodynamic therapy: basic principle. Lasers in Ophthalmology - Basic, Diagnostic and Surgical Aspects 2003, 183-195. Kugler Publications, The Hague. F. Fankhauser, S. Kwasniewska (Eds.).
131. van den Bergh H., Ballini J.P., Sickenberg M. On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. J.Fr. D'Ophtalmol. 2004, 27:75-78.
132. Van den Bergh H., Ballini J.-P. Photodynamic therapy: basic principles and mechanisms. Lasers in Opthalmol. 2003, 183-195.
133. Wakabayashi T., Gomi F., Sawa M., Tsujikawa M., Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br. J. Ophthalmol. 2008, 92:936-940.
134. Wang J.S., Kefalov V.J. The cone-specific visual cycle. Prog. Retin. Eye Res. 2011, 30:115-128.
135. Weiss A., van den Bergh H., Griffioen A.W., Nowak-Sliwinska P. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. BBA Rev. Cancer 2012, 1826:53-70.
136. Wen F., Chen C., Wu D., Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefe's Arch. Clin. Exper Ophthalmol. 2004, 242:625-629.
137. Wielgus A.R., Roberts J.E. Retinal photodamage by endogenous and xenobiotic agents. Photochem. Photobiol. 2012, 88:1320-1345.
138. Yamashita A., Shiraga F., Shiragami C., Ono A., Tenkumo K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2010, 149:465-471. e461.
139. Yamashita A., Shiraga F., Shiragami C., Shirakata Y., Fujiwara A. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2012, 57(3):283-293.
140. Yannuzzi L.A., Ciardella A., Spaide R.F., Rabb M., Freund K.B., Orlock D.A. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch. Ophthalmol. 1997, 115:478-485.
141. Yannuzzi L.A., Sorenson J., Spaide R.F., Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990, 10:1-8.
142. Yannuzzi L.A., Sorenson J., Spaide R.F., Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990. Retina 2012, 32(Suppl.1):1-8.
143. Yip P.P., Woo C.F., Tang H.H., Ho C.K. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br. J. Ophthalmol. 2009, 93:754-758.
144. Yoshida Y., Kohno T., Yamamoto M., Yoneda T., Iwami H., Shiraki K. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2013, 57(3):283-293.
145. Young R.W. The renewal of photoreceptor cell outer segments. J.Cell Biol. 1967, 33:61-72.
146. Yuzawa M., Mori R., Haruyama M. Astudy of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2003, 47:379-384.
147. Yuzawa M., Mori R., Kawamura A. The origins of polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2005, 89(5):602-607.
148. Zhang X., Wen F., Zuo C., Li M., Chen H., Wu K. Association of genetic variation on chromosome 9p21 with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. IOVS 2011, 52:8063-8067.
149. Zieve P.D., Solomon H.M., Krevans J.R. The effect of hematoporphyrin and light on human platelets. I. Morphologic, functional, and biochemical changes. J.Cell Physiol. 1966, 67:271-279.